Covid: AstraZeneca vaccine 79% effective with no increased blood clot risk – US trial
by Sarah Boseley and agencies from on (#5FMJ6)
Study of over 32,000 people included review of risks of cerebral venous sinus thrombosis
The Covid-19 vaccine developed by Oxford University and AstraZeneca was 79% effective in preventing symptomatic illness in a large trial in the US, Chile and Peru, the company said on Monday, paving the way for it to apply for US approval.
The vaccine was 100% effective against severe or critical disease and hospitalisation and was safe, the drugmaker said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups.
Continue reading...